SR34006 Compared to Vitamin K Antagonist (VKA) in the Treatment of Pulmonary Embolism

NCT ID: NCT00062803

Last Updated: 2009-04-29

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Study Classification

INTERVENTIONAL

Study Start Date

2003-06-30

Study Completion Date

2005-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Patients who have a pulmonary embolism (blood clot in the lung) will be treated in this study. The purpose of the study is to compare the safety and effectiveness of a new injectable anticoagulant (blood-thinning) drug, SR34006, with the standard way of treating a pulmonary embolism. The standard treatment includes injections or infusions of an anticoagulant drug, (LMW)heparin, for about a week followed by anticoagulant tablets (warfarin or acenocoumarol) which are taken by mouth.

Assignment to either SR34006 or (LMW)heparin plus warfarin or acenocoumarol will be purely by chance and will be known by both patients and their doctors.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pulmonary Embolism

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

SR34006

Intervention Type DRUG

(LMW)heparin

Intervention Type DRUG

Warfarin VKA

Intervention Type DRUG

Acenocoumarol VKA

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Confirmed acute symptomatic Pulmonary Embolism (PE) with or without concomitant Deep Vein Thrombosis (DVT)
* Written informed consent

Exclusion Criteria

* Legal lower age limitations (country specific)
* Thrombectomy, insertion of a caval filter, or use of a fibrinolytic agent to treat the current episode of PE
* Other indication for VKA than PE/DVT
* More than 36 hours pre-randomization treatment with therapeutic dosages of (LMW)heparin or initiation of VKA treatment prior to randomization
* Participation in another pharmacotherapeutic study within the prior 30 days
* Creatinine clearance \<10 mL/min, severe hepatic disease, or bacterial endocarditis
* Life expectancy \<3 months
* Active bleeding or high risk for bleeding
* Uncontrolled hypertension: systolic blood pressure \>180 mm Hg or diastolic blood pressure \>110 mm Hg
* Pregnancy or childbearing potential without proper contraceptive measures or women who are breastfeeding
* Any other contraindication listed in the labeling of warfarin, acenocoumarol, unfractionated heparin, enoxaparin, or tinzaparin
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Sanofi

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

sanofi-aventis

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

ICD CSD

Role: STUDY_DIRECTOR

Sanofi

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Jerry L. Pettic VA Medical Center

Loma Linda, California, United States

Site Status

University of California, San Diego Medical Center

San Diego, California, United States

Site Status

Anschutz Cancer Pavilion

Aurora, Colorado, United States

Site Status

University of Colorado Hospital

Denver, Colorado, United States

Site Status

Bay Pines VA Medical Center

Bay Pines, Florida, United States

Site Status

Brandon Regional Hospital

Brandon, Florida, United States

Site Status

Holmes Regional Medical Center

Melbourne, Florida, United States

Site Status

Jackson Memorial Hospital

Miami, Florida, United States

Site Status

St. Joseph's Hospital

Tampa, Florida, United States

Site Status

Medical College of Georgia

Augusta, Georgia, United States

Site Status

DeKalb Medical Center

Decatur, Georgia, United States

Site Status

Loyola University Medical Center and Outpatient Clinic

Maywood, Illinois, United States

Site Status

Olathe Medical Center

Olathe, Kansas, United States

Site Status

Christus St. Patrick Hospital

Lake Charles, Louisiana, United States

Site Status

Sinai Hospital of Baltimore

Baltimore, Maryland, United States

Site Status

Boston Medical Center

Boston, Massachusetts, United States

Site Status

Baystate Medical Center

Springfield, Massachusetts, United States

Site Status

Henry Ford Hospital

Detroit, Michigan, United States

Site Status

St. Joseph Mercy - Oakland

Pontiac, Michigan, United States

Site Status

William Beaumont Hospital

Royal Oak, Michigan, United States

Site Status

William Beaumont Hospital

Troy, Michigan, United States

Site Status

Lovelace Health Systems, Clinical Thrombosis Center

Albuquerque, New Mexico, United States

Site Status

Winthrop Pulmonary Associates

Mineola, New York, United States

Site Status

Winthrop University Hospital

Mineola, New York, United States

Site Status

Mount Sinai School of Medicine

New York, New York, United States

Site Status

St. Luke's-Roosevelt Hospital Center

New York, New York, United States

Site Status

University of North Carolina Hospitals

Chapel Hill, North Carolina, United States

Site Status

Altru Health System Hospital

Grand Forks, North Dakota, United States

Site Status

Akron General Medical Center

Akron, Ohio, United States

Site Status

Riverside Methodist Hospital

Columbus, Ohio, United States

Site Status

Medical College of Ohio

Toledo, Ohio, United States

Site Status

Saint Anthony Hospital

Oklahoma City, Oklahoma, United States

Site Status

Oklahoma City VA Medical Center

Oklahoma City, Oklahoma, United States

Site Status

OU Medical Center

Oklahoma City, Oklahoma, United States

Site Status

INTEGRIS Southwest Medical Center

Oklahoma City, Oklahoma, United States

Site Status

Lehigh Valley Hospital

Allentown, Pennsylvania, United States

Site Status

Crozer-Chester Medical Center

Upland, Pennsylvania, United States

Site Status

Spartanburg Regional Medical Center

Spartanburg, South Carolina, United States

Site Status

Mary Black Memorial Hospital

Spartanburg, South Carolina, United States

Site Status

Baptist Memorial Hospital Memphis

Memphis, Tennessee, United States

Site Status

The West Cancer Clinic

Memphis, Tennessee, United States

Site Status

Northwest Texas Healthcare System

Amarillo, Texas, United States

Site Status

The Methodist Hospital

Houston, Texas, United States

Site Status

Scott & White Memorial Hospital & Clinic

Temple, Texas, United States

Site Status

The University of Texas Health Center at Tyler

Tyler, Texas, United States

Site Status

University Hospital

Salt Lake City, Utah, United States

Site Status

Inova Alexandria Hospital

Alexandria, Virginia, United States

Site Status

MedSource, Inc.

Chesapeake, Virginia, United States

Site Status

Portsmouth Pulmonary Associates

Chesapeake, Virginia, United States

Site Status

Pulmonary Associates of Fredericksburg, Inc.

Fredericksburg, Virginia, United States

Site Status

Maryview Medical Center

Portsmouth, Virginia, United States

Site Status

McGuire VA Medical Center

Richmond, Virginia, United States

Site Status

Swedish Medical Center

Seattle, Washington, United States

Site Status

Sacred Heart Medical Center

Spokane, Washington, United States

Site Status

Buenos Aires, , Argentina

Site Status

Box Hill, Clayton, Garran, Kogarah, Ringwood East, , Australia

Site Status

Saint Leonards, South Australia, , Australia

Site Status

Graz, , Austria

Site Status

Bruxelles, Charleroi, Leuven, Liege, Yvoir, , Belgium

Site Status

Goiania, Porto Alegre, Sao Paulo, Salvador, , Brazil

Site Status

University of Alberta Hospital

Edmonton, Alberta, Canada

Site Status

Kelowna General Hospital

Kelowna, British Columbia, Canada

Site Status

St. Paul's Hospital

Vancouver, British Columbia, Canada

Site Status

St. Boniface General Hospital

Winnipeg, Manitoba, Canada

Site Status

QEII Health Sciences Center

Halifax, Nova Scotia, Canada

Site Status

Hamilton Health Sciences - General Hospital

Hamilton, Ontario, Canada

Site Status

London Health Sciences Centre

London, Ontario, Canada

Site Status

Ottawa Hospital - Civic Campus

Ottawa, Ontario, Canada

Site Status

University Health Network, Toronto General Hospital

Toronto, Ontario, Canada

Site Status

Humber River Regional Hospital

Weston, Ontario, Canada

Site Status

Jewish General Hospital

Montreal, Quebec, Canada

Site Status

Hotel-Dieu de St-Jerome

Saint-Jérôme, Quebec, Canada

Site Status

Brno, Jihlava, Karlovy Vary, Kladno, Ostrava Poruba, Prague, , Czechia

Site Status

Pilsen, , Czechia

Site Status

Arhus, Frederiksberg, Glostrup, Hillerod, Kobenhavn, Odense, , Denmark

Site Status

Roskilde, , Denmark

Site Status

Hus, Jyvaskyla, Seinajoki, Turku, , Finland

Site Status

Armentieres, Besancon, Bethune, Brest, Chambray Les Tours, , France

Site Status

Clamart, Lens, Lille, Nice, Nimes, Paris, Rennes, Roubaix, , France

Site Status

Saint Malo, Valenciennes, , France

Site Status

Tourcoing, , France

Site Status

Augsburg, Berlin, Bochum, Dresden, Garmisch-Partenkirchen, , Germany

Site Status

Heidelberg, Ibbenburen, Mannheim, Munchen, , Germany

Site Status

Cremona, Fidenza, Genova, Lecco, Milano, Padova, Parma, Pavia, , Italy

Site Status

Piacenza, Pisa, Reggio Emilia, Treviso, Venezia, , Italy

Site Status

Alkmaar, Amersfoort, Amsterdam, Breda, Gouda, Groningen, , Netherlands

Site Status

Haarlem, Maastricht, Nieuwegein, , Netherlands

Site Status

Oslo, Rud, , Norway

Site Status

Lublin, Warszawa, Wroclaw, , Poland

Site Status

Badalona, Madrid, Sevilla, , Spain

Site Status

Goteborg, Jonkoping, Stockholm, Varnamo, , Sweden

Site Status

Basel, Bern, Lugano, , Switzerland

Site Status

London, , United Kingdom

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Argentina Australia Austria Belgium Brazil Canada Czechia Denmark Finland France Germany Italy Netherlands Norway Poland Spain Sweden Switzerland United Kingdom

References

Explore related publications, articles, or registry entries linked to this study.

Prins MH, Guillemin I, Gilet H, Gabriel S, Essers B, Raskob G, Kahn SR. Scoring and psychometric validation of the Perception of Anticoagulant Treatment Questionnaire (PACT-Q). Health Qual Life Outcomes. 2009 Apr 7;7:30. doi: 10.1186/1477-7525-7-30.

Reference Type DERIVED
PMID: 19348685 (View on PubMed)

van Gogh Investigators; Buller HR, Cohen AT, Davidson B, Decousus H, Gallus AS, Gent M, Pillion G, Piovella F, Prins MH, Raskob GE. Idraparinux versus standard therapy for venous thromboembolic disease. N Engl J Med. 2007 Sep 13;357(11):1094-104. doi: 10.1056/NEJMoa064247.

Reference Type DERIVED
PMID: 17855670 (View on PubMed)

Related Links

Access external resources that provide additional context or updates about the study.

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

EFC3484

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

The DARE Warfarin CER Study
NCT03271450 UNKNOWN